Innovation1 Biotech Inc., a drug discovery company, focuses on the development of modified schedule 1 molecules of botanical origin in the United States. Its portfolio includes five proprietary fully synthetic preclinical prodrugs addressing independent clinical indications comprising a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression; a novel cannabinoid and tree bark derived psychedelic for treatment of addiction; and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. The company was formerly known as Gridiron BioNutrients, Inc. and changed its name to Innovation1 Biotech Inc. in March 2022. Innovation1 Biotech Inc. was founded in 2014 and is headquartered in New York, New York.